Summary: Researchers have created an AI-based method that uses brain scans and clinical information to predict, within one week, whether the antidepressant sertraline will be effective for a patient with major depressive disorder. This approach can reduce unnecessary prescriptions, limit side effects, and speed up access to effective treatments, advancing personalized care and lowering social and economic costs associated with prolonged depression.
The prediction model emphasizes cerebral blood flow in the anterior cingulate cortex combined with early symptom severity. By identifying likely non-responders rapidly, clinicians could avoid weeks of ineffective treatment and start alternative therapies sooner.
Key Facts:
- The AI algorithm can indicate likely antidepressant efficacy up to eight weeks earlier than standard clinical evaluation.
- Applied to the study data, the model identified approximately one-third of patients who would respond to sertraline, allowing clinicians to avoid prescribing the drug to the two-thirds unlikely to benefit.
- The findings support a move toward individualized depression treatment and may change routine care by reducing trial-and-error prescribing.
Source: University of Amsterdam
Overview
Researchers at Amsterdam UMC and Radboudumc applied an artificial intelligence algorithm to MRI data and clinical information to predict antidepressant response much earlier than current practice allows. The study, now published in the American Journal of Psychiatry, demonstrates that combining neuroimaging markers with clinical measures can provide actionable predictions about sertraline effectiveness within the first week of treatment.
Professor Liesbeth Reneman, neuroradiologist at Amsterdam UMC, notes that standard practice typically requires six to eight weeks to determine whether an antidepressant is working. This delay often subjects patients to prolonged symptoms and potential side effects before a treatment change is made. The new predictive approach aims to shorten that timeline substantially.
The analysis used data from a prior U.S. study in which 229 patients with major depressive disorder underwent MRI scanning and clinical assessment before and after one week of treatment with either sertraline or placebo. The Amsterdam-based team trained and tested an algorithm on that dataset to evaluate whether early brain and clinical signals could forecast longer-term response to sertraline.
Results showed the model could identify roughly one in three patients who would benefit from sertraline, meaning two-thirds could be spared an unnecessary prescription. Eric Ruhé, psychiatrist at Radboudumc, explains that the algorithm highlighted blood flow in the anterior cingulate cortex—a brain region involved in emotion regulation—as a key predictor. Symptom severity at the one-week follow-up added further predictive power.
Clinical implications
If validated and implemented in clinical settings, this method could transform how antidepressants are prescribed. Today, clinicians typically start a medication and wait six to eight weeks, or sometimes longer, to evaluate effectiveness. Patients who do not respond are switched to alternative medications, a process that can repeat multiple times and prolong suffering. Early prediction of non-response would allow clinicians to explore other therapies sooner, whether alternative medications, psychotherapy, or neuromodulation techniques, improving outcomes and reducing time spent in debilitating depression.
Beyond individual benefit, faster identification of effective versus ineffective treatments could reduce societal costs tied to lost productivity and healthcare utilization when depressive episodes continue unresolved.
Next steps
Despite promising results, the researchers acknowledge the need to refine and validate the algorithm in larger and more diverse patient samples. They plan to enhance the model by incorporating additional clinical and biological information to improve accuracy and generalizability. Continued work will focus on translating the tool into a practical aid for clinicians while ensuring it complements clinical judgment and established treatment pathways.
About this AI and psychopharmacology research news
Author: Jack Cairns
Source: University of Amsterdam
Contact: Jack Cairns – University of Amsterdam
Image: The image is credited to Neuroscience News
Original Research: Findings published in the American Journal of Psychiatry